• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 12.42
  • VXN 17.07
  • VXO 11.36
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
IMMU (Immunomedics Inc.)
Last Trade 21.78 Dividend/Share 0 PE Ratio -26.56
Date September 25-2018 Dividend Yield 0.000 Return on Assets -66.24
Change 0 ExDividend Date 0 Return on Capital null
Bid 21.8 Latest EPS -1.9 Price/Sale 1,882.189
Ask 22.1 LatestEPS Date 2018-06-30 Price to Book 10.13
Volume 0 EPS ttm -0.82 Institutional % 75.8
Avg Volume 1.58M Shares Outstanding 186.83M Insider % 1.4
Open 21.76 Float 184.59M Short Ratio 12.450
Prev Close 21.78 Return On Equity -160.23 5 Year Change % 2.541
High 22.24 Consensus EPS -0.1 2 Year Change % 5.681
Low 21.68 No. of Estimate 2.000 1 Year Change % 0.729
52 Week High 27.33 EPS Surprise $ null YTD Change % 0.368
52 Week Low 8.68 EPS Surprise Percent -90 6 Month Change % 0.370
52 Week Change 72.857 EBITDA -117.74M 3 Month Change % -0.091
50 Day MA 23.641 Revenue 1.29M 1 Month Change % -0.022
200 Day MA 19.52615 Gross Profit 0.72M 5 Day Change % -0.013
Market Cap 4069.2M Cash 279.38M 30 Day Change % -0.031
Beta 1.807561 Debt 0M Stock Exchange NASDAQ Global Market
Sector Healthcare Revenue Per Share 0 Short Interest 18.13M
Short Date 2018-08-31 Revenue Per Employee 6961 Short Ratio 12.450
Company Profile

Immunomedics, Inc. engages in the research, development, manufacture, and marketing of monoclonal antibody-based products for the treatment of cancer, and autoimmune and other serious diseases. Its products include epratuzumab, a Phase III clinical trail product for the treatment of systemic lupus erythematosus and non-Hodgkin?s lymphoma; Veltuzumab, a Phase I/II clinical study product for the treatment of patients with non-Hodgkin?s lymphoma, immune thrombocytopenic purpura, and chronic lymphocytic leukemia; Yttrium Y 90 Clivatuzumab tetraxetan, a humanized monoclonal antibody for pancreatic cancer that is in Phase Ib clinical trail; and Yttrium Y 90 epratuzumab tetraxetan, a Phase I/II clinical study product for patients with non-Hodgkin?s lymphoma. The company?s preclinal trial products comprise Milatuzumab, a transmembrane protein product for antibody-drug immunoconjugate therapy; and Labetuzumab, a product candidate that targets colon, rectum, breast, lung, and other solid tumors. In addition, the company markets and sells a diagnostic product, ?LeukoScan?, which is used to treat infection and inflammation in bones for patients with suspected osteomyelitis, including patients with diabetic foot ulcers. It also develops Dock-and-Lock method technology that combines conjugation chemistry and genetic engineering to enable the creation of novel human therapeutics, and the construction of enhanced recombinant products. The company distributes its products in the United States, Europe, and Japan. Immunomedics has a license and collaboration agreement with Nycomed GmbH to develop, manufacture, and commercialize veltuzumab in the subcutaneous formulation for the treatment of various non-cancer indications; and a partnership and cross-licensing agreement with Alexis Biotech Ltd. to develop vaccines against melanoma and chronic lymphocytic leukemia, and infectious diseases, such as AIDS. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.